


Accepted Manuscript



Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease (SSc-ILD): Results of Scleroderma Lung Study II

Donald P. Tashkin, MD, Elizabeth R. Volkmann, MD, Chi-Hong Tseng, PhD, Michael D. Roth, MD, Dinesh Khanna, MD, Daniel E. Furst, MD, Philip J. Clements, MD, Arthur Theodore, MD, Suzanne Kafaja, MD, Grace Hyun Kim, PhD, Jonathan Goldin, MD, Edgar Ariolla, PharmD, Robert M. Elashoff, PhD

PII: S0012-3692(16)62590-4

DOI: [10.1016/j.chest.2016.11.052](https://doi.org/10.1016/j.chest.2016.11.052)

Reference: CHEST 868

To appear in: *CHEST*

Received Date: 29 August 2016

Revised Date: 10 November 2016

Accepted Date: 21 November 2016

Please cite this article as: Tashkin DP, Volkmann ER, Tseng CH, Roth MD, Khanna D, Furst DE, Clements PJ, Theodore A, Kafaja S, Kim GH, Goldin J, Ariolla E, Elashoff RM, Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease (SSc-ILD): Results of Scleroderma Lung Study II, *CHEST* (2017), doi: 10.1016/j.chest.2016.11.052.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Word Count: Abstract 250; Text 2725

TITLE: Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease (SSc-ILD): Results of Scleroderma Lung Study II

SHORT TITLE/RUNNING HEAD

Cough in Scleroderma-Interstitial Lung Disease

Donald P. Tashkin, MD¹, Elizabeth R. Volkman, MD¹, Chi-Hong Tseng, PhD¹, Michael D. Roth, MD¹, Dinesh Khanna, MD², Daniel E. Furst, MD¹, Philip J. Clements, MD¹, Arthur Theodore, MD³, Suzanne Kafaja, MD¹, Grace Hyun Kim, PhD¹, Jonathan Goldin, MD¹, Edgar Ariolla¹, PharmD, and Robert M. Elashoff, PhD¹

¹David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹University of Michigan Medical School, Ann Arbor, MI, and ¹Boston University School of Medicine, Boston, MA

e-mail addresses: DPT: dtashkin@mednet.ucla.edu; EV: evolkman@mednet.ucla.edu; C-HT: ctseng@mednet.ucla.edu; MDR: mroth@mednet.ucla.edu; DK: khanna@med.umich.edu; DEF: defurst@mednet.ucla.edu; PC: pclements@mednet.ucla.edu; AT: atheodor@bu.edu; SK: skafaja@mednet.ucla.edu; GHK: GraceKim@mednet.ucla.edu; JG: jgoldin@mednet.ucla.edu; RE: relashof@biomath.ucla.edu

Summary of conflict of interest statements: DPT served as a consultant to EMD Serono; MDR received a contract for study drug supply from Roche in support of SLS II; DK is funded by NIH/NIAMS (K24AR063120), received grant support from Bayer, Bristol-Meyer-Squibb (BMS), Roche/Genentech and Pfizer and served as a consultant to Actelion, BMS, Corbus, Roche/Genentech, GlaxoSmithKlein, Sanofi-Aventis and EMD Serono; DEF received grant support from Amgen, BMS, Novartis, Pfizer and Roche/Genentech and served as a consultant to AbbVie, Amgen, BMS, Cytori, Janssen, Novartis, Pfizer, Roche/Genetech and UCB pharma. C-HT, PC, AT, SK, GHK, JG and RME report no conflict of interest

Funded by the NHLBI (R01 HL089758 and R01 GK089901)

Corresponding author:

**Donald P. Tashkin, MD
Department of Medicine
David Geffen School of Medicine at UCLA
10833 Le Conte Ave.
Los Angeles, CA 90095 USA
dtashkin@mednet.ucla.edu – e-mail**

ABBREVIATION LIST:

Download English Version:

<https://daneshyari.com/en/article/5600344>

Download Persian Version:

<https://daneshyari.com/article/5600344>

[Daneshyari.com](https://daneshyari.com)